Oder Investment Management’s Karyopharm Therapeutics KPTI Stock Holding History

Oder Investment Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-112	Closed	-$26K	–	312
2020 Q4	$26K	Buy	+112	New	+$26K	0.03%	252

Other funds holding KPTI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

DMPV

Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Oder Investment Management's KPTI Position: Q1 2021 in Review

Oder Investment Management sold out of Karyopharm Therapeutics (KPTI) in Q1 2021, closing a stake of 112 shares — an estimated $26K sold.

Oder Investment Management first reported a position in KPTI in Q4 2020 and held it in 1 quarter. The position peaked at $26K in Q4 2020. 171 funds tracked by Wall St. Rank hold KPTI as of Q1 2021.

Oder Investment Management reported no remaining Karyopharm Therapeutics position as of Q1 2021 after selling out during the quarter.
Oder Investment Management sold 112 Karyopharm Therapeutics shares in Q1 2021, an estimated $26K.
Oder Investment Management first reported a position in Karyopharm Therapeutics in Q4 2020 and held it in 1 quarter.
Oder Investment Management's Karyopharm Therapeutics position peaked at $26K in Q4 2020.
171 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2021.

Based on Oder Investment Management's 13F filing for Q1 2021, filed 10 May 2021.